Smith & Nephew plc (LON:SN - Get Free Report) passed above its two hundred day moving average during trading on Monday . The stock has a two hundred day moving average of GBX 1,055.89 ($14.18) and traded as high as GBX 1,140 ($15.31). Smith & Nephew shares last traded at GBX 1,122.50 ($15.07), with a volume of 1,274,729 shares.
Smith & Nephew Stock Performance
The stock's 50 day moving average price is GBX 1,091.56 and its 200 day moving average price is GBX 1,058.38. The company has a current ratio of 2.51, a quick ratio of 0.84 and a debt-to-equity ratio of 70.22. The company has a market capitalization of £12.27 billion, a price-to-earnings ratio of 40.31, a P/E/G ratio of 0.46 and a beta of 0.62.
Insider Activity at Smith & Nephew
In other news, insider Jeremy (Jez) Maiden acquired 1,855 shares of the firm's stock in a transaction that occurred on Thursday, May 1st. The shares were acquired at an average cost of GBX 1,070 ($14.37) per share, with a total value of £19,848.50 ($26,653.01). Corporate insiders own 0.19% of the company's stock.
About Smith & Nephew
(
Get Free Report)
Smith & Nephew plc, together with its subsidiaries, develops, manufactures, markets, and sells medical devices and services in the United Kingdom and internationally. It operates through three segments: Orthopaedics, Sports Medicine & ENT, and Advanced Wound Management. The company offers knee implant products for knee replacement procedures; hip implants for revision procedures; trauma and extremities products that include internal and external devices used in the stabilization of severe fractures and deformity correction procedures; and other reconstruction products.
See Also
Before you consider Smith & Nephew, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Smith & Nephew wasn't on the list.
While Smith & Nephew currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2025. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
